Inhibitors & Agonists

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC8088	CYM5442 Featured	CYM-5442 is a highly-selective S1P1 (Spingosine 1-Phosphate Receptor 1) agonist.
DC20352	CYP11B1-IN-25	CYP11B1-IN-25 is a selective, potent 11β-hydroxylase (CYP11B1) inhibitor with IC50 of 2 nM, displays 14-fold selectivity over CYP11B2.
DCAPI1536	Cyproheptadine Hydrochloride	Cyproheptadine hydrochloride is a migraine prophylactic and Non-selective SR-2A (5HT2) antagonist. Cyproheptadine hydrochloride is an inhibitor of Histamine H1 Receptor and SR-2C.
DC3107	Momelotinib (CYT387,CYT-387) Featured	CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively.
DC5134	lexibulin (CYT997)	CYT997 is a potent microtubule polymerization inhibitor with IC50 of 10-100 nM in cancer cell lines. Phase 1/2.
DCAPI1295	Cytidine	Cytidine
DC9835	Cytochalasin H Featured	Cytochalasin H is a potent inhibitor of actin incorporation into filaments,a cell-permeable fungal toxin used in actin polymerization studies and cytological research.
DCAPI1566	Cytarabine hydrochloride Featured	Cytosine β-D-arabinofuranoside hydrochloride is an anti-leukemic agent which binds to topoisomerase I resulting in DNA fragmentation and inhibition of replication. In addition this compound does not have any effects on RNA synthesis. Cytosine β-D-arabinof
DC10125	CZ415 Featured	CZ415 is a potent and highly selective mTOR inhibitor.
DC7734	CZC24832 Featured	CZC24832 is the first selective PI3Kγinhibitor with IC50 of 27 nM, with 10-fold selectivity over PI3Kβ and >100-fold selectivity over PI3Kα and PI3Kδ.
DC7113	CZC-25146 Featured	CZC-25146 is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
DC8082	CZC-54252 Featured	CZC-54252 is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively).
DC11199	CZh226 Featured	CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.
DC11198	CZh226 hydrochloride	CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.
DC9886	D-(+)-Cellobiose	D-(+)-Cellobiose is a substrate of β-glucosidase.
DC12252	D,L-Buthionine-(S,R)-sulfoximine Featured	D,L-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
DC12582	D13-9001	D13-9001 (D 13-9001) is a small molecule, MexAB-OprM specific efflux pump inhibitor with good potency in vitro (MPC 2 ug/mL) and displays excellent activity in vivo in a rat pneumonia model of P. aeruginosa..
DC25001	D-156844	D156844 is a potent SMN2 inducer and DcpS inhibitor.
DC12610	D159153	D159153 (D-159153) is a novel potent, allosteric inhibitor of PDE4 with cellular IC50 of 28.5 and 6.6 nM for PDE4B1 and PDE4D3, respectively..
DC20219	D159687 Featured	D159687 is a selective negative allosteric modulator (NAM) of PDE4D.
DC9850	D-3263 HCl Featured	D3263 is a novel, orally bioavailable small molecule Trp-p8 agonist.
DC7011	D4476 (D-4476) Featured	D4476, a cell-permeant inhibitor of CK1δ (IC90 <10 uM), suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a, D4476 originally identified as inhibitors of activin receptor-like kinase ALK5.
DC11124	D-520	D-520 is a potent, multifunctional D2/D3 agonist with Ki of 41.8 /0.35 nM, modulates aggregation of alpha-synuclein (αSN) and reduces toxicity of preformed aggregates of αSN.
DC20053	D5D-IN-326	D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and d
DC9589	D609 Featured	D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM); antiviral and antitumor agent.
DC7393	D-64131 Featured	D-64131 is a novel inhibitor of Tubulin polymerization that competitively binds with [(3)H]colchicine to αβ-Tubulin.
DC11232	D715-2441	D715-2441 (D 715-2441) is a novel antiviral compound that interferes with the conserved cap-binding domain of the PB2 protein, exhibits potent antiviral activity against influenza A viruses (IAVs) with IC50 of 1.7-4.4 uM.
DC9259	DAA1106 Featured	DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors, in mitochondrial fractions of the rat brain.
DC8913	Dabigatran etexilate mesylate Featured	Dabigatran etexilate mesylate (BIBR 1048MS) serves as the orally bioavailable prodrug of the active anticoagulant dabigatran. Following absorption, this precursor compound undergoes enzymatic conversion to release dabigatran - a highly selective, reversible direct thrombin inhibitor (DTI) with exceptional potency (Ki = 4.5 nM).
DC5149	Dabrafenib Featured	Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3.

Inhibitors & Agonists

Customized Consultation X

Your information is safe with us. * Required Fields.